2008-2021: U.S. new drug listing prices rose nearly 90 times
- The first Alzheimer’s disease Aβ and Tau pathological surrounding cell structure and gene expression map
- Magic TCR-T cell therapy: 72% of tumor lesions disappeared
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
2008-2021: U.S. new drug listing prices rose nearly 90 times
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
2008-2021: U.S. new drug listing prices rose nearly 90 times
On June 7, Harvard Medical School professors Aaron S. Kesselheim, Benjamin N. Rome and assistant researcher Alexander C. Egilman published “Trends in Prescription Drug Launch Prices, 2008-2021” article.
A total of 548 (95%) of the 576 drugs that were first marketed between 2008 and 2021 were included in the study, 3 diagnostic drugs and 25 drugs for which annual prices could not be estimated were excluded.
Of these, 357 (65%) were new molecular entities, 139 (25%) were biologics, 182 (33%) were rare disease drugs, 64 (12%) were marketed through the accelerated approval pathway, 119 (22%) were %) is a tumor drug.
The most expensive drugs are rare disease drugs and oncology drugs, with a median price of $168,441/year and $155,091/year, respectively.
Statistics found that from 2008 to 2021, the annual growth rate of new drug listing prices was 20.4%, adjusted according to drug characteristics, 13%, and the annual growth rate of net prices was 10.7%.
The median price has increased from $2,115/yuan in 2008 to $180,007/year in 2021. The proportion of drugs priced above $150,000/year was 9% (18/197) in 2008-2013 and 47% (42/89) in 2020-2021.
The median net price has increased from $1,376/year in 2008 to $159,042/year in 2021.
The article said that new drug price growth trends outpaced other medical services, and that manufacturers routinely raise prices over time after a drug is on the market.
In response to current trends, the U.S. could stop allowing drug makers to set prices freely and follow other industrialized nations in negotiating drug prices when they come to market.
2008-2021: U.S. new drug listing prices rose nearly 90 times
(source:internet, reference only)
Disclaimer of medicaltrend.org
